이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Multimodal Assessment of Remodeling and Stratification in Heart Failure (MARS-HF)

2026년 11월 10일 업데이트: Shandong Provincial Hospital

Artificial Intelligence-Enhanced Multimodal Cardiovascular Phenotyping for Cardiac Remodeling and Risk Stratification in Ischemic and Nonischemic Acute and Chronic Heart Failure: A Prospective, Multicenter, Observational Cohort Study

Heart failure is a common condition in which the heart cannot pump blood effectively. It can be caused by reduced blood supply to the heart (ischemic) or by other causes (nonischemic), and it may begin suddenly (acute) or last for a long time (chronic). Heart failure can lead to changes in the heart's structure and function, called cardiac remodeling, and to different risks of hospitalization or death.

This is a prospective, multicenter, observational study. It will enroll adults with acute or chronic heart failure, including both ischemic and nonischemic types. Participants will receive their usual medical care and will undergo multimodal assessments. These may include cardiac magnetic resonance imaging, echocardiography, electrocardiography, blood tests, and computed tomography, including high-resolution coronary CT or photon-counting CT when available. Data on heart structure, function, blood flow, tissue characteristics, and clinical outcomes will be collected during follow-up.

The main goals are to better understand cardiac remodeling in different types of heart failure and to find out whether combining information from different tests can improve risk stratification. Advanced statistical methods and artificial intelligence will be explored as part of the analysis, but artificial intelligence is not the main focus; the study aims to integrate all data sources in a balanced way. No new drug or device will be tested. The results may help doctors improve how they evaluate and monitor patients with heart failure.

연구 개요

상태

모병

정황

상세 설명

Detailed Description

Heart failure is a heterogeneous clinical syndrome in which the heart cannot pump blood effectively. Patients with heart failure differ widely in cause, presentation, cardiac structure and function, and prognosis. Ischemic and nonischemic heart failure, as well as acute and chronic heart failure, may have different patterns of cardiac remodeling and different risks of adverse events. Standard clinical assessment, laboratory tests, and single imaging methods provide important but incomplete information. Combining multiple sources of data may give a more complete picture of the disease and may improve risk stratification.

This is a prospective, multicenter, observational cohort study. It will enroll adults with acute or chronic heart failure, including both ischemic and nonischemic causes. Participants will receive their usual medical care. No experimental drug, device, or treatment will be administered. Treatment decisions will remain at the discretion of the treating physicians.

The study will collect clinical, electrocardiographic, laboratory, and multimodal imaging data using a standardized protocol. Multimodal assessments may include cardiac magnetic resonance imaging, echocardiography, electrocardiography, blood tests, and computed tomography. Cardiac magnetic resonance parameters may include late gadolinium enhancement, extracellular volume, T1 mapping, T2 mapping, strain, cardiac diffusion tensor imaging, four-dimensional flow, and stress perfusion. Computed tomography may include CT angiography and, when available, photon-counting CT for high-resolution coronary imaging. Echocardiography may include chamber size, systolic and diastolic function, strain, and valve assessment. Laboratory tests may include biomarkers such as natriuretic peptides, troponin, renal function, and other clinically relevant markers.

The main objectives are:

To characterize cardiac remodeling across ischemic, nonischemic, acute, and chronic heart failure using integrated multimodal data.

To evaluate the associations between multimodal markers and clinical outcomes.

To develop and validate risk stratification models that combine information from different modalities in a balanced way.

To compare the incremental value of advanced imaging and clinical parameters beyond conventional assessment.

To explore artificial intelligence and other advanced analytical methods as part of the analysis, although artificial intelligence is not the main focus of the study.

Participants will be followed for [e.g., 12 to 24 months] according to the study protocol. Data will be collected at baseline and at prespecified follow-up visits. Clinical outcomes may include death, heart failure hospitalization, major adverse cardiovascular events, arrhythmia, changes in symptoms and functional status, and changes in cardiac structure and function. Outcome information will be obtained from clinic visits, medical records, telephone contact, and registries where available.

Statistical analysis will include descriptive analyses, regression models, survival analyses, and advanced modeling methods. Artificial intelligence and machine learning will be explored as one of several analytical approaches, alongside conventional statistical methods. Models will be internally validated, and external validation will be performed if feasible. Missing data will be handled using appropriate methods, and subgroup analyses will be performed for ischemic versus nonischemic and acute versus chronic heart failure.

This study may improve the understanding of cardiac remodeling in different types of heart failure and may help identify patients at higher risk. The results may support the development of more comprehensive and balanced multimodal assessment strategies and may inform future clinical studies. The study will be conducted in accordance with ethical principles and applicable regulations. Institutional review board or ethics committee approval will be obtained, and informed consent will be required from all participants.

연구 유형

관찰

등록 (추정된)

2000

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Liaoning
      • Shenyang, Liaoning, 중국
        • 모병
        • The First Affiliated Hospital of China Medical University
    • Shandong
      • Jinan, Shandong, 중국
        • 모병
        • Shandong Provincial Hospital Affiliated to Shandong First Medical University
        • 연락하다:
      • Jinan, Shandong, 중국
        • 모병
        • Jinan central hospital
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 어린이
  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

샘플링 방법

확률 샘플

연구 인구

Patients with DCM, HCM, myocarditis, or ischemic and non-ischemic chronic and acute heart failure meeting the composite clinical diagnosis

설명

Dilated Cardiomyopathy Inclusion criteria: Diagnosed dilated cardiomyopathy (DCM) according to the World Health Organization / International Society and Federation of Cardiology (WHO/ISFC) criteria, characterized by elevated body surface area-indexed left ventricular end-diastolic volume and left ventricular ejection fraction (LVEF) below published age- and sex-specific reference values.

Exclusion criteria: Severe coronary artery disease (CAD, defined as >50% stenosis of a major coronary artery), infiltrative cardiomyopathy, arrhythmogenic

HCM Inclusion criteria: The diagnosis of hypertrophic cardiomyopathy is independently made by clinicians according to current guidelines, based on imaging examinations including CMR, electrocardiography, family history and genetic testing (if available). Inclusion criterion: left ventricular wall thickness ≥13 mm in ≥1 myocardial segment on CMR.

Exclusion criteria: Apical hypertrophic myocardial infarction, any contraindications to CMR, adenosine or gadolinium (Gd)-based contrast agents, systemic hypertension, severe valvular disease, infiltrative cardiomyopathy, prior myocardial infarction or coronary intervention.

Chronic Heart Failure Inclusion criteria: age ≥18 years; established clinical diagnosis of chronic heart failure for at least 3 months based on current guideline criteria; NYHA class I-IV; LVEF assessed within 12 months by echocardiography, CMR, or other validated imaging, meeting HFrEF (LVEF ≤40%), HFmrEF (LVEF 41-49%), or HFpEF (LVEF ≥50%); for HFpEF, at least one supportive finding documented within 12 months (elevated NT-proBNP >125 pg/mL or BNP >35 pg/mL, structural heart disease such as left atrial enlargement, left ventricular hypertrophy, or diastolic dysfunction, or prior heart failure hospitalization); stable clinical condition with no change in NYHA class or heart failure-specific therapy within 7 days before enrollment; receiving guideline-directed medical therapy at a stable dose for at least 4 weeks unless contraindicated or not tolerated; ability to provide written informed consent Exclusion criteria:General: age <18 years; pregnant or breastfeeding; women of childbearing potential unwilling to use effective contraception during the study; life expectancy <12 months due to non-cardiac disease; concurrent acute coronary syndrome at screening (typical chest pain with troponin above 99th percentile and electrocardiographic changes suggestive of ischemia); history of cardiac transplantation or current ventricular assist device; prior solid organ transplantation; systolic blood pressure <90 mmHg or mean arterial pressure <65 mmHg at screening; estimated glomerular filtration rate <30 mL/min/1.73 m²; renal replacement therapy or ultrafiltration before enrollment; severe hepatic impairment (Child-Pugh class C); known or suspected non-cardiac cirrhosis; active malignancy or current treatment for malignancy that may affect participation or outcomes; any condition that may interfere with compliance or compromise data quality. CMR-specific: any absolute contraindication to MRI including non-MR-conditional pacemaker or implantable cardioverter-defibrillator, intracranial aneurysm clips, metallic intraocular foreign body, cochlear/otological/ear implant, neurostimulator, or non-MR-conditional monitoring/support devices; severe claustrophobia not manageable with preparation or mild sedation; contraindication to gadolinium-based contrast agents including previous anaphylactic reaction, eGFR <30 mL/min/1.73 m², known nephrogenic systemic fibrosis, or pregnancy; inability to lie flat or hold breath sufficiently for image acquisition; clinically unstable condition precluding safe MRI. Stress perfusion-specific: previous anaphylactic reaction to adenosine, regadenoson, or dobutamine; severe obstructive airways disease or mild-to-moderate disease with contraindication to adenosine/regadenoson; high-degree atrioventricular block or symptomatic bradycardia (<40 beats per minute) without functioning pacemaker; symptomatic severe or critical aortic stenosis; known left ventricular thrombus; uncontrolled arterial hypertension or uncontrolled atrial fibrillation during imaging; acute coronary or aortic syndrome within 7 days before imaging; concomitant theophylline, dipyridamole, or caffeine within 6-12 hours before stress perfusion imaging.

Acute decompensated heart failure Inclusion criteria: male or female adults aged ≥18 years; current hospitalization or unscheduled clinic/emergency department visit for a primary diagnosis of acute decompensated heart failure (de novo or decompensation of chronic heart failure) regardless of LVEF category (HFrEF, HFmrEF, or HFpEF); at least one clinical sign of volume overload (peripheral edema score ≥2, pulmonary congestion or pleural effusion on chest X-ray or ultrasound, ascites on ultrasound, or elevated jugular venous pressure); elevated natriuretic peptides (NT-proBNP >1000 pg/mL or BNP >250 pg/mL); receiving or anticipated to receive intravenous diuretic therapy during the index hospitalization or acute care episode; for HFpEF, diagnosis supported by structural heart disease and/or diastolic dysfunction plus elevated natriuretic peptides; ability to provide written informed consent or consent from a legally authorized representative if temporarily unable. Exclusion criteria:General: age <18 years; pregnant or breastfeeding; women of childbearing potential unwilling to use effective contraception during the study; life expectancy <12 months due to non-cardiac disease; concurrent acute coronary syndrome at screening (typical chest pain with troponin above 99th percentile and electrocardiographic changes suggestive of ischemia); history of cardiac transplantation or current ventricular assist device; prior solid organ transplantation; systolic blood pressure <90 mmHg or mean arterial pressure <65 mmHg at screening; estimated glomerular filtration rate <30 mL/min/1.73 m²; renal replacement therapy or ultrafiltration before enrollment; severe hepatic impairment (Child-Pugh class C); known or suspected non-cardiac cirrhosis; active malignancy or current treatment for malignancy that may affect participation or outcomes; any condition that may interfere with compliance or compromise data quality. CMR-specific: any absolute contraindication to MRI including non-MR-conditional pacemaker or implantable cardioverter-defibrillator, intracranial aneurysm clips, metallic intraocular foreign body, cochlear/otological/ear implant, neurostimulator, or non-MR-conditional monitoring/support devices; severe claustrophobia not manageable with preparation or mild sedation; contraindication to gadolinium-based contrast agents including previous anaphylactic reaction, eGFR <30 mL/min/1.73 m², known nephrogenic systemic fibrosis, or pregnancy; inability to lie flat or hold breath sufficiently for image acquisition; clinically unstable condition precluding safe MRI. Stress perfusion-specific: previous anaphylactic reaction to adenosine, regadenoson, or dobutamine; severe obstructive airways disease or mild-to-moderate disease with contraindication to adenosine/regadenoson; high-degree atrioventricular block or symptomatic bradycardia (<40 beats per minute) without functioning pacemaker; symptomatic severe or critical aortic stenosis; known left ventricular thrombus; uncontrolled arterial hypertension or uncontrolled atrial fibrillation during imaging; acute coronary or aortic syndrome within 7 days before imaging; concomitant theophylline, dipyridamole, or caffeine within 6-12 hours before stress perfusion imaging.

myocarditis Inclusion Criteria: Male or female adults aged ≥18 years; diagnosis of myocarditis confirmed by at least one of the following: (a) cardiac magnetic resonance fulfilling the modified Lake Louise Criteria (at least one T2-based criterion for myocardial edema AND at least one T1-based criterion including native T1 mapping, extracellular volume, or late gadolinium enhancement in a non-ischemic distribution), OR (b) endomyocardial biopsy demonstrating histologic, immunologic, and immunohistochemical evidence of myocardial inflammation; OR (c) in patients with high clinical pretest probability, a combination of at least one clinical presentation (acute chest pain, dyspnea, palpitations, arrhythmia, syncope, or unexplained cardiogenic shock) AND at least one diagnostic finding (elevated cardiac troponin, ECG changes suggestive of myocardial injury, or echocardiographic evidence of new regional or global wall motion abnormality) AND CMR findings consistent with myocardial inflammation; time from symptom onset classified as acute (<4 weeks), subacute (4-12 weeks), or chronic (>3 months); for chronic myocarditis, persistent or recurrent symptoms or imaging evidence of ongoing myocardial inflammation for >3 months from initial onset; receiving standard clinical care, including guideline-directed medical therapy for heart failure when applicable; ability to provide written informed consent prior to any study-related assessment, or consent from a legally authorized representative if temporarily unable.

CAD: were the following: (1) age > 18 years; (2) CAD diagnosed according to current guidelines [10, 11]-(a) atleast 70% stenosis in one or more coronary arteries or > 50% stenosis of the left main stem in percutaneous coronary intervention (PCI) or computed tomography angiography (CTA); (b) history of severe angina or myocardial infarction (MI); (c) previous revascularization history, including surgical coronary artery bypass grafting (CABG).The exclusion criteria were the following: (1) definite non-ischemic heart disease; (2)acute MI; (3) any contraindication to CMR.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
Patient group

Participants enrolled who meet the diagnostic criteria according to clinical guidelines and the inclusion and exclusion criteria

Healthy volunteers

Healthy volunteer group matched with the patient group for age and sex

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Heart failure-related composite endpoint
기간: At 3, 6, 12, 24, 36 and 48 months after CMR examination

The prespecified primary endpoint was a composite of heart failure (HF) events, including HF-related death, unplanned HF hospitalization, or cardiac transplantation. Death was attributed to HF if progressive worsening of HF symptoms and signs occurred before death. HF hospitalization was defined as admission due to new or worsening HF symptoms and signs requiring intensified HF-specific therapy.

At 3, 6, 12, 24, 36 and 48 months after CMR examination

2차 결과 측정

결과 측정
측정값 설명
기간
Sudden Cardiac Death (SCD)-related endpoint
기간: At 3, 6, 12, 24, 36 and 48 months after CMR examination

The prespecified primary endpoint of this study was a composite of SCD-related events, including SCD, appropriate ICD shock, and resuscitated cardiac arrest.

At 3, 6, 12, 24, 36 and 48 months after CMR examination

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2022년 12월 1일

기본 완료 (추정된)

2029년 9월 10일

연구 완료 (추정된)

2030년 9월 10일

연구 등록 날짜

최초 제출

2026년 11월 10일

QC 기준을 충족하는 최초 제출

2026년 11월 10일

처음 게시됨 (실제)

2026년 11월 17일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 17일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • SWYX:NO.2025-524

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .